Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.34 |
| ▸ | ARG2 | P78540 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.32 |
| ▸ | GABRD | O14764 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8995125 | 0.82 | GABRR1 (0.36) | GABRR1KDM4ECYP1A2CYP2D6CACNA2D1 | |
| SCHEMBL9952000 | 0.76 | ALDH1A1 (0.33) | CYP1A2CYP2D6ARG1ARG2ADRA1A | |
| Ammonia Solution, Strong SCHEMBL27560424 | 0.74 | ALDH1A1 (0.32) | CYP1A2CYP2D6ARG1ARG2 | |
| SCHEMBL1643768 | 0.74 | CYP2C19 (0.46) | KDM4ECYP1A2CYP2D6ADRA1A | |
| SCHEMBL9342339 | 0.72 | HDAC1 (0.33) | CYP1A2ARG1ARG2ADRA1AGGT1 | |
| SCHEMBL29777967 | 0.72 | ARG1 (0.50) | GABRR1KDM4ECYP1A2CYP2D6ARG1 | |
| SCHEMBL136592 | 0.72 | LMNA (0.42) | CYP1A2OR51E2 | |
| SCHEMBL2142717 | 0.70 | CYP1A2 (0.43) | CYP1A2CYP2D6ARG1ARG2GABRP | |
| SCHEMBL14809159 | 0.69 | TSHR (0.48) | OR51E2 | |
| SCHEMBL14809752 | 0.69 | TSHR (0.48) | OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102046602-A | Process for the preparation of montelukast intermediates | SYNTHON BV | 2011-05-04 | — | — | CN | disclosed |
| EP-2276739-A1 | PROCESS FOR MAKING MONTELUKAST INTERMEDIATES | Synthon B.V. (NL) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009130056-A1 | PROCESS FOR MAKING MONTELUKAST INTERMEDIATES | SYNTHON B.V. (NL) | 2009-10-29 | — | — | WO | disclosed |
| US-20090270628-A1 | PROCESS FOR MAKING MONTELUKAST INTERMEDIATES | SYNTHON BV (NL) | 2009-10-29 | — | — | US | disclosed |
| WO-2008034122-A2 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008034119-A2 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270628-A1 | PROCESS FOR MAKING MONTELUKAST INTERMEDIATES | LTB4R2, CYSLTR2, CYSLTR1 | GABRR1 2243/4885KDM4E 4735/4885CYP1A2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.